SEC Form 4 · accession 0001203311-18-000087
SEATTLE GENETICS INC /WA · SGEN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Clay B Siegall
Officer — President and CEO · Director
Period of report
Sep 17, 2018
Accepted (ET)
Sep 19, 2018 · 6:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001060736
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 17, 2018 | M | 9,931 | $12.16 | A | 742,544 | D | |
| Common StockF3,F1 | Sep 17, 2018 | S | 9,931 | $76.36 | D | 732,613 | D | |
| Common StockF1 | Sep 17, 2018 | M | 8,827 | $12.16 | A | 741,440 | D | |
| Common StockF4,F1 | Sep 17, 2018 | S | 8,827 | $77.20 | D | 732,613 | D | |
| Common StockF1 | Sep 17, 2018 | M | 1,390 | $12.16 | A | 734,003 | D | |
| Common StockF5,F1 | Sep 17, 2018 | S | 1,390 | $78.00 | D | 732,613 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F6 | $12.16 | Sep 17, 2018 | M | 9,931 | D | — | Aug 25, 2019 | Common Stock | 9,931 | 231,846 | D |
| Non-Qualified Stock Option (right to buy)F6 | $12.16 | Sep 17, 2018 | M | 8,827 | D | — | Aug 25, 2019 | Common Stock | 8,827 | 223,019 | D |
| Non-Qualified Stock Option (right to buy)F6 | $12.16 | Sep 17, 2018 | M | 1,390 | D | — | Aug 25, 2019 | Common Stock | 1,390 | 221,629 | D |
Explanation of responses
- F1Amount of securities beneficially owned following reported transactions includes restricted stock units subject to vesting.
- F2The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
- F3Reflects sales of common stock executed in multiple transactions at prices ranging from $75.81 to $76.80. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F4Reflects sales of common stock executed in multiple transactions at prices ranging from $76.81 to $77.80. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F5Reflects sales of common stock executed in multiple transactions at prices ranging from $77.83 to $78.25. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.
- F6Shares vested at a rate of 25% on 8/25/10 and monthly thereafter until all the shares were fully vested on 8/25/13.